| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Afshar Amiri, Ahmad-Ali Noorbala, Ali-Akbar Nejatisafa, Abolfazl Ghoreishi, Mohammad-Kamran Derakhshan, Mohammad-Reza Khodaie-Ardakani, Mohammad Hajiazim, Maedeh Raznahan, Shahin Akhondzade. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Human psychopharmacology. vol 23. issue 2. 2008-03-14. PMID:17972359. |
efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. |
2008-03-14 |
2023-08-12 |
Not clear |
| Afshar Amiri, Ahmad-Ali Noorbala, Ali-Akbar Nejatisafa, Abolfazl Ghoreishi, Mohammad-Kamran Derakhshan, Mohammad-Reza Khodaie-Ardakani, Mohammad Hajiazim, Maedeh Raznahan, Shahin Akhondzade. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Human psychopharmacology. vol 23. issue 2. 2008-03-14. PMID:17972359. |
this study was designed to investigate the effect of selegiline added to risperidone as augmentation therapy in patients with chronic schizophrenia and prominent negative symptoms in an 8 week, double blind and randomized clinical trial. |
2008-03-14 |
2023-08-12 |
Not clear |
| P-M Llorca, E Sacchetti, K Lloyd, W Kissling, R Medor. Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months. International journal of clinical pharmacology and therapeutics. vol 46. issue 1. 2008-02-29. PMID:18218293. |
long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months. |
2008-02-29 |
2023-08-12 |
Not clear |
| Mark Olfson, Steven C Marcus, Haya Ascher-Svanu. Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. Schizophrenia bulletin. vol 33. issue 6. 2008-02-27. PMID:17470444. |
treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. |
2008-02-27 |
2023-08-12 |
Not clear |
| Mark Olfson, Steven C Marcus, Haya Ascher-Svanu. Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. Schizophrenia bulletin. vol 33. issue 6. 2008-02-27. PMID:17470444. |
this study compares 3 cohorts of patients with schizophrenia before, during, and after initiating treatment with fluphenazine decanoate (fd), haloperidol decanoate (hd), or long-acting injectable risperidone (lar). |
2008-02-27 |
2023-08-12 |
Not clear |
| Manuel Gurpegui, Enrique Alvarez, Manuel Bousoño, Antonio Ciudad, Juan Carlos Gómez, José Manuel Olivare. Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 17. issue 11. 2008-02-27. PMID:17543505. |
effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms. |
2008-02-27 |
2023-08-12 |
Not clear |
| Manuel Gurpegui, Enrique Alvarez, Manuel Bousoño, Antonio Ciudad, Juan Carlos Gómez, José Manuel Olivare. Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 17. issue 11. 2008-02-27. PMID:17543505. |
to compare olanzapine and risperidone outcome on some neurocognitive dimensions in chronic schizophrenia patients with prominent negative symptoms. |
2008-02-27 |
2023-08-12 |
Not clear |
| Mahesh B Jayaram, Prakash M Hosalli, Thomas S Strou. Risperidone versus olanzapine for treatment of schizophrenia. Schizophrenia bulletin. vol 33. issue 6. 2008-02-27. PMID:17921477. |
risperidone versus olanzapine for treatment of schizophrenia. |
2008-02-27 |
2023-08-12 |
Not clear |
| Simon A Surguladze, Elvina M Chu, Anthony Evans, Anantha P P Anilkumar, Maxine X Patel, Clive Timehin, Anthony S Davi. The effect of long-acting risperidone on working memory in schizophrenia: a functional magnetic resonance imaging study. Journal of clinical psychopharmacology. vol 27. issue 6. 2008-02-26. PMID:18004121. |
the effect of long-acting risperidone on working memory in schizophrenia: a functional magnetic resonance imaging study. |
2008-02-26 |
2023-08-12 |
Not clear |
| Simon A Surguladze, Elvina M Chu, Anthony Evans, Anantha P P Anilkumar, Maxine X Patel, Clive Timehin, Anthony S Davi. The effect of long-acting risperidone on working memory in schizophrenia: a functional magnetic resonance imaging study. Journal of clinical psychopharmacology. vol 27. issue 6. 2008-02-26. PMID:18004121. |
we used functional magnetic resonance imaging to examine cortical systems supporting working memory in patients with schizophrenia treated with risperidone long-acting injections (rlais) versus those on conventional depot medication (conv). |
2008-02-26 |
2023-08-12 |
Not clear |
| Matcheri S Keshavan, Konasale M Prasad, Debra M Montrose, Jean M Miewald, David J Kupfe. Sleep quality and architecture in quetiapine, risperidone, or never-treated schizophrenia patients. Journal of clinical psychopharmacology. vol 27. issue 6. 2008-02-26. PMID:18004141. |
sleep quality and architecture in quetiapine, risperidone, or never-treated schizophrenia patients. |
2008-02-26 |
2023-08-12 |
Not clear |
| Takefumi Suzuki, Hiroyuki Uchida, Koichiro Watanabe, Kensuke Nomura, Hiroyoshi Takeuchi, Masayuki Tomita, Kenichi Tsunoda, Shintaro Nio, Ryoske Den, Hiroshi Manki, Akira Tanabe, Gohei Yagi, Haruo Kashim. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. Psychopharmacology. vol 195. issue 2. 2008-02-25. PMID:17701027. |
how effective is it to sequentially switch among olanzapine, quetiapine and risperidone?--a randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. |
2008-02-25 |
2023-08-12 |
Not clear |
| Seiya Miyamoto, Nobumi Miyake, Shin Ogino, Takako Endo, Noboru Yamaguch. Successful treatment of Meige's syndrome induced by risperidone and fluvoxamine with olanzapine monotherapy in schizophrenia. Psychiatry and clinical neurosciences. vol 61. issue 6. 2008-02-14. PMID:18081639. |
successful treatment of meige's syndrome induced by risperidone and fluvoxamine with olanzapine monotherapy in schizophrenia. |
2008-02-14 |
2023-08-12 |
Not clear |
| Lei Wang, Lan Yu, Ai-Ping Zhang, Chao Fang, Jing Du, Niu-Fan Gu, Sheng-Ying Qin, Guo-Yin Feng, Xing-Wang Li, Qing-He Xing, Lin H. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia. Journal of psychopharmacology (Oxford, England). vol 21. issue 8. 2008-01-29. PMID:17715206. |
serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome p450 2d6 and clinical response in patients with schizophrenia. |
2008-01-29 |
2023-08-12 |
Not clear |
| Lei Wang, Lan Yu, Ai-Ping Zhang, Chao Fang, Jing Du, Niu-Fan Gu, Sheng-Ying Qin, Guo-Yin Feng, Xing-Wang Li, Qing-He Xing, Lin H. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia. Journal of psychopharmacology (Oxford, England). vol 21. issue 8. 2008-01-29. PMID:17715206. |
one-hundred and eighteen chinese schizophrenia patients (40 males, 78 females, age 15-60 years) were given risperidone at dosages ranging from 2-8 mg/day for 8 weeks. |
2008-01-29 |
2023-08-12 |
Not clear |
| Theo C Manschreck, Roger A Boshe. The CATIE schizophrenia trial: results, impact, controversy. Harvard review of psychiatry. vol 15. issue 5. 2008-01-23. PMID:17924259. |
the catie (clinical antipsychotic trials for intervention effectiveness) schizophrenia trial was designed to examine fundamental issues about second-generation antipsychotic (sga) medications (olanzapine, risperidone, quetiapine, and ziprasidone) - their relative effectiveness and their effectiveness compared to a first-generation antipsychotic (fga), perphenazine. |
2008-01-23 |
2023-08-12 |
human |
| Qinghe Xing, Xueqing Qian, Huafang Li, Shiming Wong, Shengnan Wu, Guoyin Feng, Shiwei Duan, Mingqing Xu, Rui Gao, Wei Qin, Jianjun Gao, Junwei Meng, Lin H. The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. The international journal of neuropsychopharmacology. vol 10. issue 5. 2008-01-17. PMID:17105675. |
the relationship between the therapeutic response to risperidone and the dopamine d2 receptor polymorphism in chinese schizophrenia patients. |
2008-01-17 |
2023-08-12 |
Not clear |
| Qinghe Xing, Xueqing Qian, Huafang Li, Shiming Wong, Shengnan Wu, Guoyin Feng, Shiwei Duan, Mingqing Xu, Rui Gao, Wei Qin, Jianjun Gao, Junwei Meng, Lin H. The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. The international journal of neuropsychopharmacology. vol 10. issue 5. 2008-01-17. PMID:17105675. |
these data suggest that the drd2 a-241g polymorphism or, alternatively, another genetic variation that is in linkage disequilibrium, may influence response to risperidone in schizophrenia patients. |
2008-01-17 |
2023-08-12 |
Not clear |
| Marcia F T Rupnow, Andrew Greenspan, Georges M Gharabawi, Colette Kosik-Gonzalez, Young Zhu, Stephen M Stah. Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder. Current medical research and opinion. vol 23. issue 11. 2008-01-16. PMID:17910802. |
incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder. |
2008-01-16 |
2023-08-12 |
Not clear |
| Leslie Citrome, Constance B Shope, Karen A Nolan, Pal Czobor, Jan Volavk. Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. International clinical psychopharmacology. vol 22. issue 6. 2008-01-14. PMID:17917554. |
risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. |
2008-01-14 |
2023-08-12 |
Not clear |